Dianne Pappachristou
Family Medicine · Quincy, FLNPI 1427014133
Payments from drug & device makers
Across 265 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Pfizer$466
- Boehringer Ingelheim$369
- AstraZeneca$339
- Abbott$265
- AbbVie$245
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,848100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $1,071 |
| Pfizer | 31 | $466 |
| Boehringer Ingelheim | 19 | $369 |
| AstraZeneca | 16 | $339 |
| Abbott | 12 | $265 |
| AbbVie(2 entities) | 15 | $245 |
| Sanofi-aventis U.S. LLC | 12 | $213 |
| Lilly USA, LLC | 14 | $209 |
| Dexcom, Inc. | 5 | $203 |
| Merck | 13 | $172 |
| Astellas Pharma US Inc | 9 | $161 |
| GSK | 8 | $143 |
| Amgen(2 entities) | 4 | $132 |
| Phathom Pharmaceuticals, Inc. | 5 | $92 |
| Bayer | 6 | $89 |
| Novartis | 5 | $85 |
| Johnson & Johnson | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| Teva Pharmaceuticals USA, Inc. | 5 | $76 |
| Exact Sciences | 4 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $40 |
| Amarin Pharma, Inc. | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $32 |
| Organon | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Shire North American Group Inc | 1 | $14 |
| Global Blood Therapeutics, Inc. | 1 | $13 |
How this compares
$4,848 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 146 | $147,868 |
| RybelsusSemaglutide | 39 | $56,695 |
| JanuviaSitagliptin Phosphate | 45 | $46,570 |
| EliquisApixaban | 40 | $39,431 |
| OzempicSemaglutide | 23 | $35,986 |
| FarxigaDapagliflozin Propanediol | 33 | $28,113 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $14,871 |
| Victoza 3-PakLiraglutide | 15 | $13,133 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,708 |
| Losartan Potassium | 409 | $5,459 |
| Atorvastatin Calcium | 307 | $5,437 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $5,043 |
| SynthroidLevothyroxine Sodium | 31 | $3,964 |
| Amlodipine Besylate | 379 | $2,944 |
| Clonidine | 32 | $2,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $369 | $147,868146 claims |
| Novo NordiskRybelsus, Ozempic | $1,071 | $92,68162 claims |
| MerckJanuvia | $172 | $46,57045 claims |
| PfizerEliquis | $466 | $39,43140 claims |
| AstraZenecaFarxiga, Symbicort | $339 | $33,82046 claims |
| AbbVieSynthroid | $245 | $3,96431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Quincy
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.